{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:32:00Z","timestamp":1789122720930,"version":"build-2803163510"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Evidences supporting the use of myeloablative-dose Treosulfan combined with Fludarabine remain largely retrospective, with outdated prospective studies available. In this phase II multicenter prospective trial, we evaluated the safety and efficacy of FT14 conditioning regimen in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in first complete remission.(EudraCT Number:2021-006515-28; Clinical trial number NCT07232953). The study was designed to provide a non-inferior alternative to standard busulfan-containing regimens, which would enable effective transplantation while minimizing toxicity. The primary objective was 1-year Leukemia-free survival (LFS). In total, 82 patients were enrolled in the study with a median follow up of 19.7 months; donor used were matched sibling in 22, matched unrelated 52 and mismatched unrelated in 8 cases, respectively. LFS at 180-day and 365-day were 87.8% and 81.7%, respectively. Cumulative incidence of relapse at 1 year after allo-HSCT was 14.9% with mean time to relapse of 5.6 months. Also, FT14 regimen provided an excellent safety with nearly absent NRM, no cases of septic death, and no cases of primary graft failure. Our study supports the use of FT14 as effective myeloablative conditioning regimen for AML patients aged 40\u201365\u2009y in first complete remission, especially in patients for whom busulfan based conditioning regimens poses excessive toxic risks.<\/jats:p>","DOI":"10.1038\/s41409-026-02937-7","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T07:45:35Z","timestamp":1782287135000},"page":"1176-1181","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transplantation for AML patients aged 40\u201365 in first complete remission"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4218-4170","authenticated-orcid":false,"given":"Daniele","family":"Avenoso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Radici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Leoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Skert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3987-419X","authenticated-orcid":false,"given":"Massimo","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4969-1434","authenticated-orcid":false,"given":"Nicola","family":"Mordini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6500-9514","authenticated-orcid":false,"given":"Francesco","family":"Saraceni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9089-9328","authenticated-orcid":false,"given":"Attilio","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4001-1607","authenticated-orcid":false,"given":"Cristina","family":"Tecchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0136-7686","authenticated-orcid":false,"given":"Alessandra","family":"Picardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Saporiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Patriarca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bresciani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Nozzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Maravalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6297-9697","authenticated-orcid":false,"given":"Nicola","family":"Polverelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Magliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Morello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2980-9028","authenticated-orcid":false,"given":"Mirko","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3494-2624","authenticated-orcid":false,"given":"Simona","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4219-8695","authenticated-orcid":false,"given":"Federica","family":"Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Garuffo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Maifredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Zanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"De Domenico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0907-130X","authenticated-orcid":false,"given":"Michele","family":"Malagola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,24]]},"reference":[{"key":"2937_CR1","unstructured":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN | Blood | American Society of Hematology. https:\/\/ashpublications.org\/blood\/article\/140\/12\/1345\/485817\/Diagnosis-and-management-of-AML-in-adults-2022 Accessed 28 Oct 2025."},{"key":"2937_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41409-024-02248-9","volume":"59","author":"JR Passweg","year":"2024","unstructured":"Passweg JR, Baldomero H, Ciceri F, de la C\u00e1mara R, Glass B, Greco R, et al. Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT. Bone Marrow Transplant. 2024;59:803.","journal-title":"Bone Marrow Transplant"},{"key":"2937_CR3","doi-asserted-by":"publisher","unstructured":"Russo D, Polverelli N, Bernardi S, Santarone S, Farina M, Borlenghi E, et al. Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2024; 0. https:\/\/doi.org\/10.1016\/S2352-3026(24)00241-2","DOI":"10.1016\/S2352-3026(24)00241-2"},{"key":"2937_CR4","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.3390\/jcm14082759","volume":"14","author":"M Farina","year":"2025","unstructured":"Farina M, Malagola M, Bernardi S, Re F, Russo D, Avenoso D. Intensive Chemotherapy Versus Venetoclax-Based Regimens in Elderly Patients with Acute Myeloid Leukemia: Is the Chemotherapy Era Ending? J Clin Med. 2025;14:2759.","journal-title":"J Clin Med"},{"key":"2937_CR5","doi-asserted-by":"publisher","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","volume":"4","author":"O Penack","year":"2020","unstructured":"Penack O, Peczynski C, Mohty M, Yakoub-Agha I, Styczynski J, Montoto S, et al. How much has allogeneic stem cell transplant\u2013related mortality improved since the 1980s? A retrospective analysis from the EBMT. Blood Advances. 2020;4:6283\u201390.","journal-title":"Blood Advances"},{"key":"2937_CR6","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","volume":"7","author":"O Penack","year":"2020","unstructured":"Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Review Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. The Lancet Haematology. 2020;7:e157\u201367.","journal-title":"The Lancet Haematology"},{"key":"2937_CR7","first-page":"3221","volume":"73","author":"JA Maertens","year":"2018","unstructured":"Maertens JA, Girmenia C, Br\u00fcggemann RJ, Duarte RF, Kibbler CC, Ljungman P, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73:3221\u201330.","journal-title":"J Antimicrob Chemother"},{"key":"2937_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41409-023-02124-y","volume":"59","author":"M Malagola","year":"2024","unstructured":"Malagola M, Radici V, Farina M, Pellizzeri S, Spoldi F, Morello E, et al. CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation. Bone Marrow Transplant. 2024;59:138\u201340.","journal-title":"Bone Marrow Transplant"},{"key":"2937_CR9","doi-asserted-by":"publisher","first-page":"874117","DOI":"10.3389\/fonc.2022.874117","volume":"12","author":"M Malagola","year":"2022","unstructured":"Malagola M, Turra A, Signorini L, Corbellini S, Polverelli N, Masina L, et al. Results of an Innovative Program for Surveillance, Prophylaxis, and Treatment of Infectious Complications Following Allogeneic Stem Cell Transplantation in Hematological Malignancies (BATMO Protocol). Front Oncol. 2022;12:874117.","journal-title":"Front Oncol"},{"key":"2937_CR10","doi-asserted-by":"publisher","first-page":"534268","DOI":"10.3389\/fcell.2020.534268","volume":"8","author":"M Malagola","year":"2020","unstructured":"Malagola M, Pollara C, Polverelli N, Zollner T, Bettoni D, Gandolfi L, et al. Advances in CMV Management: A Single Center Real-Life Experience. Front Cell Dev Biol. 2020;8:534268.","journal-title":"Front Cell Dev Biol"},{"key":"2937_CR11","doi-asserted-by":"publisher","first-page":"e2017036","DOI":"10.4084\/mjhid.2017.036","volume":"9","author":"M Malagola","year":"2017","unstructured":"Malagola M, Rambaldi B, Ravizzola G, Cattaneo C, Borlenghi E, Polverelli N, et al. Bacterial Blood Stream Infections Negatively Impact on Outcome of Patients Treated with Allogeneic Stem Cell Transplantation: 6 Years Single-Centre Experience. Mediterr J Hematol Infect Dis. 2017;9:e2017036.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2937_CR12","doi-asserted-by":"publisher","first-page":"96.e1","DOI":"10.1016\/j.jtct.2021.11.006","volume":"28","author":"M Malagola","year":"2022","unstructured":"Malagola M, Polverelli N, Rubini V, Martino M, Patriarca F, Bruno B, et al. GITMO Registry Study on Allogeneic Transplantation in Patients Aged \u226560 Years from 2000 to 2017: Improvements and Criticisms. Transplantation and Cellular Therapy. Official Publication of the American Society for Transplantation and Cellular Therapy. 2022;28:96.e1\u201396.e11.","journal-title":"Official Publication of the American Society for Transplantation and Cellular Therapy"},{"key":"2937_CR13","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","volume":"7","author":"DW Beelen","year":"2020","unstructured":"Beelen DW, Trenschel R, Stelljes M, Groth C, Masszi T, Rem\u00e9nyi P, et al. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14\/L): a randomised, non-inferiority, phase 3 trial. Lancet Haematol. 2020;7:e28\u2013e39.","journal-title":"Lancet Haematol"},{"key":"2937_CR14","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","volume":"16","author":"A Rambaldi","year":"2015","unstructured":"Rambaldi A, Grassi A, Masciulli A, Boschini C, Mic\u00f2 MC, Busca A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. The Lancet Oncology. 2015;16:1525\u201336.","journal-title":"The Lancet Oncology"},{"key":"2937_CR15","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/cam4.3593","volume":"10","author":"F Saraceni","year":"2020","unstructured":"Saraceni F, Labopin M, Forcade E, Kr\u00f6ger N, Soci\u00e9 G, Niittyvuopio R, et al. Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). Cancer Med. 2020;10:23\u201333.","journal-title":"Cancer Med"},{"key":"2937_CR16","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/s41409-024-02329-9","volume":"59","author":"D Avenoso","year":"2024","unstructured":"Avenoso D, Lionel S, Maraj A. Second allogeneic haematopoietic stem cell transplant conditioned with treosulfan and fludarabine is associated with encouraging overall survival and transplant related mortality in late relapse of myeloid malignancies. Bone Marrow Transpl. 2024;59:1313\u20135.","journal-title":"Bone Marrow Transpl"},{"key":"2937_CR17","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41409-023-02028-x","volume":"58","author":"E Gavriilaki","year":"2023","unstructured":"Gavriilaki E, Sakellari I, Labopin M, Bornh\u00e4user M, Hamladji R-M, Casper J, et al. Survival advantage of treosulfan plus fludarabine (FT14) compared to busulfan plus fludarabine (FB4) in active acute myeloid leukemia post allogeneic transplantation: an analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP). Bone Marrow Transplant. 2023;58:1084\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2937_CR18","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1038\/s41409-022-01830-3","volume":"57","author":"E Gavriilaki","year":"2022","unstructured":"Gavriilaki E, Labopin M, Sakellari I, Salmenniemi U, Yakoub-Agha I, Potter V, et al. Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP). Bone Marrow Transplant. 2022;57:1803\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"2937_CR19","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/s41409-022-01646-1","volume":"57","author":"J Duque-Afonso","year":"2022","unstructured":"Duque-Afonso J, Finke J, Labopin M, Craddock C, Protheroe R, Kottaridis P, et al. Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2022;57:1269\u201376.","journal-title":"Bone Marrow Transplant"},{"key":"2937_CR20","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Borowitz MJ, Beau MML, Bloomfield CD, et al. The 2016 revision to the World Health Organization classi fi cation of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013406.","journal-title":"Blood"},{"key":"2937_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"2937_CR22","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753\u201367.","journal-title":"Blood"},{"key":"2937_CR23","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.humimm.2021.07.013","volume":"82","author":"AG Blouin","year":"2021","unstructured":"Blouin AG, Ye F, Williams J, Askar M. A Practical Guide To Chimerism Analysis: Review of The Literature and Testing Practices Worldwide. Hum Immunol. 2021;82:838\u201349.","journal-title":"Hum Immunol"},{"key":"2937_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jinf.2017.10.009","volume":"76","author":"M Mikulska","year":"2018","unstructured":"Mikulska M, Averbuch D, Tissot F, Cordonnier C, Akova M, Calandra T, et al. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Infect. 2018;76:20\u201337.","journal-title":"J Infect"},{"key":"2937_CR25","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. New England Journal of Medicine. 2017;377:2433\u201344.","journal-title":"New England Journal of Medicine"},{"key":"2937_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.beha.2008.02.005","volume":"21","author":"T Toubai","year":"2008","unstructured":"Toubai T, Sun Y, Reddy P. GVHD pathophysiology: is acute different from chronic? Best Pract Res Clin Haematol. 2008;21:101\u201317.","journal-title":"Best Pract Res Clin Haematol"},{"key":"2937_CR27","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M, Aerts E, Alaskar AS, Aljurf M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: A new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation. 2016;51:906\u201312.","journal-title":"Bone Marrow Transplantation"},{"key":"2937_CR28","doi-asserted-by":"crossref","unstructured":"Avenoso D, Kenyon M, Mehra V, Krishnamurthy P, Kulasekararaj A, Gandhi S, et al. Systematic screening and focused evaluation for veno-occlusive disease\/sinusoidal obstructive syndrome (VOD\/SOS) following allogeneic stem cell transplant is associated with earlier diagnosis and prompt institution of defibrotide treatment. Front Transplant. 2022;1. https:\/\/www.frontiersin.org\/articles\/10.3389\/frtra.2022.996003. (accessed 29 Mar 2023).","DOI":"10.3389\/frtra.2022.996003"},{"key":"2937_CR29","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.bbmt.2017.12.776","volume":"24","author":"A Shimoni","year":"2018","unstructured":"Shimoni A, Labopin M, Savani B, Hamladji R-M, Beelen D, Mufti G, et al. Intravenous Busulfan Compared with Treosulfan-Based Conditioning for Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: A Study on Behalf of the Acute Leukemia Working Party of European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2018;24:751\u20137.","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02937-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02937-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02937-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:37:35Z","timestamp":1789119455000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02937-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2937"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02937-7","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,24]]},"assertion":[{"value":"21 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}